Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPTRAUMA: intermediate versus standard-dose enoxaparin in severe trauma
2025-522832-16-00Phase 3Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enoxaparin and Placebo-COD Research Private Ltd in Major trauma (2 arms), sponsored by CHU Grenoble Alpes. Planned start Dec 2025; status: authorised.
02
Drugs
enoxaparinPlacebo-COD Research Private Ltd
03
Conditions
Major trauma
Beyond the preview
Go deeper on 2025-522832-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522832-16-00.